


BOARD INFORMATION

CONTACT INFORMATION:

Arizona Board of Osteopathic Examiners
(480) 657-7703

RELEASE DATE:

January 23, 2023



IMPORTANT UPDATE: Elimination of the DEA DATA-waiver requirement.

NOTICE:

The Drug Enforcement Administration has made our organization aware that they have eliminated the requirement for DATA-waiver registration for professionals to prescribe buprenorphine to treat opioid use disorder. The DEA stated, "On December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the 'DATA-Waiver Program.'

All DEA registrants should be aware of the following:

- A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
- Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DA TA-Waiver registration numbers are no longer needed for any prescription.
- There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
- The Act does not impact existing state laws or regulations that may be applicable.

Separately, the Act also introduced new training requirements for all prescribers. These requirements will not go into effect until June 21, 2023. The DEA and SAMHSA are actively working to provide further guidance, and DEA will follow up with additional information on these requirements shortly. Importantly, these new requirements do not impact the changes related to the elimination of the DATA-Waiver Program described above. "

For any questions regarding the DEA and its requirements please review <https://www.DEAdiversion.usdoj.gov> or please contact the Diversion Control Division Policy Section at ODLP@dea.gov.

Link to the Notice from the DEA: [Found Here](#)

Link to guidance regarding Suspicious Order Monitoring Thresholds: [Found Here](#)

###